Soy isoflavones do not affect bone resorption in postmenopausal women

A dose-response study using a novel approach with41Ca

J. M K Cheong, B. R. Martin, G. S. Jackson, D. Elmore, G. P. McCabe, J. R. Nolan, S. Barnes, Munro Peacock, C. M. Weaver

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Introduction: The purpose of this 3-way crossover study was to identify the effective dose of soy protein isolate enriched with isoflavones for suppressing bone resorption in postmenopausal women using a novel, rapid assessment of antibone resorbing treatments. Methods: Thirteen postmenopausal women (≥6 yr since menopause) were predosed with 41Ca iv. After a 200-d baseline period, subjects were given 43 g soy protein/d that contained 0, 97.5, or 135.5 mg total isoflavones in randomized order. The soy protein isolate powder was incorporated into baked products and beverages. Each 50-d intervention phase was preceded by a 50-d pretreatment phase for comparison. Serum isoflavone levels and biochemical markers were measured at the end of each phase. Twenty-four-hour urine samples were collected approximately every 10 d during each phase for 41Ca/Ca analysis by accelerator mass spectrometry. Results: Serum isoflavone levels reflected the amount of isoflavones consumed in a dose-dependent manner. None of the isoflavone levels had a significant effect on biochemical markers of bone turnover, urinary cross-linked N teleopeptides of type I collagen and serum osteocalcin, or bone turnover as assessed by urinary 41Ca/Ca ratios. Conclusions: Soy protein with isoflavone doses of up to 135.5 mg/d did not suppress bone resorption in postmenopausal women. This is the first efficacy trial using the novel technique of urinary 41Ca excretion from prelabeled bone.

Original languageEnglish
Pages (from-to)577-582
Number of pages6
JournalJournal of Clinical Endocrinology and Metabolism
Volume92
Issue number2
DOIs
StatePublished - Feb 2007

Fingerprint

Isoflavones
Bone Resorption
Bone
Soybean Proteins
Bone Remodeling
Biomarkers
Serum
Beverages
Osteocalcin
Menopause
Collagen Type I
Powders
Cross-Over Studies
Particle accelerators
Mass spectrometry
Mass Spectrometry
Urine
Bone and Bones

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology, Diabetes and Metabolism

Cite this

Soy isoflavones do not affect bone resorption in postmenopausal women : A dose-response study using a novel approach with41Ca. / Cheong, J. M K; Martin, B. R.; Jackson, G. S.; Elmore, D.; McCabe, G. P.; Nolan, J. R.; Barnes, S.; Peacock, Munro; Weaver, C. M.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 92, No. 2, 02.2007, p. 577-582.

Research output: Contribution to journalArticle

Cheong, J. M K ; Martin, B. R. ; Jackson, G. S. ; Elmore, D. ; McCabe, G. P. ; Nolan, J. R. ; Barnes, S. ; Peacock, Munro ; Weaver, C. M. / Soy isoflavones do not affect bone resorption in postmenopausal women : A dose-response study using a novel approach with41Ca. In: Journal of Clinical Endocrinology and Metabolism. 2007 ; Vol. 92, No. 2. pp. 577-582.
@article{2d8ff71381fd4257bb0eb066817a7689,
title = "Soy isoflavones do not affect bone resorption in postmenopausal women: A dose-response study using a novel approach with41Ca",
abstract = "Introduction: The purpose of this 3-way crossover study was to identify the effective dose of soy protein isolate enriched with isoflavones for suppressing bone resorption in postmenopausal women using a novel, rapid assessment of antibone resorbing treatments. Methods: Thirteen postmenopausal women (≥6 yr since menopause) were predosed with 41Ca iv. After a 200-d baseline period, subjects were given 43 g soy protein/d that contained 0, 97.5, or 135.5 mg total isoflavones in randomized order. The soy protein isolate powder was incorporated into baked products and beverages. Each 50-d intervention phase was preceded by a 50-d pretreatment phase for comparison. Serum isoflavone levels and biochemical markers were measured at the end of each phase. Twenty-four-hour urine samples were collected approximately every 10 d during each phase for 41Ca/Ca analysis by accelerator mass spectrometry. Results: Serum isoflavone levels reflected the amount of isoflavones consumed in a dose-dependent manner. None of the isoflavone levels had a significant effect on biochemical markers of bone turnover, urinary cross-linked N teleopeptides of type I collagen and serum osteocalcin, or bone turnover as assessed by urinary 41Ca/Ca ratios. Conclusions: Soy protein with isoflavone doses of up to 135.5 mg/d did not suppress bone resorption in postmenopausal women. This is the first efficacy trial using the novel technique of urinary 41Ca excretion from prelabeled bone.",
author = "Cheong, {J. M K} and Martin, {B. R.} and Jackson, {G. S.} and D. Elmore and McCabe, {G. P.} and Nolan, {J. R.} and S. Barnes and Munro Peacock and Weaver, {C. M.}",
year = "2007",
month = "2",
doi = "10.1210/jc.2006-0369",
language = "English",
volume = "92",
pages = "577--582",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "2",

}

TY - JOUR

T1 - Soy isoflavones do not affect bone resorption in postmenopausal women

T2 - A dose-response study using a novel approach with41Ca

AU - Cheong, J. M K

AU - Martin, B. R.

AU - Jackson, G. S.

AU - Elmore, D.

AU - McCabe, G. P.

AU - Nolan, J. R.

AU - Barnes, S.

AU - Peacock, Munro

AU - Weaver, C. M.

PY - 2007/2

Y1 - 2007/2

N2 - Introduction: The purpose of this 3-way crossover study was to identify the effective dose of soy protein isolate enriched with isoflavones for suppressing bone resorption in postmenopausal women using a novel, rapid assessment of antibone resorbing treatments. Methods: Thirteen postmenopausal women (≥6 yr since menopause) were predosed with 41Ca iv. After a 200-d baseline period, subjects were given 43 g soy protein/d that contained 0, 97.5, or 135.5 mg total isoflavones in randomized order. The soy protein isolate powder was incorporated into baked products and beverages. Each 50-d intervention phase was preceded by a 50-d pretreatment phase for comparison. Serum isoflavone levels and biochemical markers were measured at the end of each phase. Twenty-four-hour urine samples were collected approximately every 10 d during each phase for 41Ca/Ca analysis by accelerator mass spectrometry. Results: Serum isoflavone levels reflected the amount of isoflavones consumed in a dose-dependent manner. None of the isoflavone levels had a significant effect on biochemical markers of bone turnover, urinary cross-linked N teleopeptides of type I collagen and serum osteocalcin, or bone turnover as assessed by urinary 41Ca/Ca ratios. Conclusions: Soy protein with isoflavone doses of up to 135.5 mg/d did not suppress bone resorption in postmenopausal women. This is the first efficacy trial using the novel technique of urinary 41Ca excretion from prelabeled bone.

AB - Introduction: The purpose of this 3-way crossover study was to identify the effective dose of soy protein isolate enriched with isoflavones for suppressing bone resorption in postmenopausal women using a novel, rapid assessment of antibone resorbing treatments. Methods: Thirteen postmenopausal women (≥6 yr since menopause) were predosed with 41Ca iv. After a 200-d baseline period, subjects were given 43 g soy protein/d that contained 0, 97.5, or 135.5 mg total isoflavones in randomized order. The soy protein isolate powder was incorporated into baked products and beverages. Each 50-d intervention phase was preceded by a 50-d pretreatment phase for comparison. Serum isoflavone levels and biochemical markers were measured at the end of each phase. Twenty-four-hour urine samples were collected approximately every 10 d during each phase for 41Ca/Ca analysis by accelerator mass spectrometry. Results: Serum isoflavone levels reflected the amount of isoflavones consumed in a dose-dependent manner. None of the isoflavone levels had a significant effect on biochemical markers of bone turnover, urinary cross-linked N teleopeptides of type I collagen and serum osteocalcin, or bone turnover as assessed by urinary 41Ca/Ca ratios. Conclusions: Soy protein with isoflavone doses of up to 135.5 mg/d did not suppress bone resorption in postmenopausal women. This is the first efficacy trial using the novel technique of urinary 41Ca excretion from prelabeled bone.

UR - http://www.scopus.com/inward/record.url?scp=33846978077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846978077&partnerID=8YFLogxK

U2 - 10.1210/jc.2006-0369

DO - 10.1210/jc.2006-0369

M3 - Article

VL - 92

SP - 577

EP - 582

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 2

ER -